Li Y, et al. - Researchers systematically examined the link between statin use and overall and cancer-specific survival in patients with colorectal cancer (CRC). For this purpose, they analyzed 14 relevant studies, with 130,994 patients, identified from PubMed, the Cochrane Library, Web of Science, EMBASE, and SCOPUS from inception to August 2017. The pooled hazard ratio of all-cause mortality (ACM) and cancer-specific mortality (CSM) was 0.85 and 0.82, respectively, for pre-diagnosis statin uses, and 0.86 and 0.79 for post-diagnosis statin uses, respectively. Stratification by KRAS gene mutation status revealed no difference in ACM for post-diagnosis statin uses. Overall, reduced ACM and CSM were reported for CRC patients in relation to both pre-diagnosis and post-diagnosis statin uses.